ApprovedFDA approval

Lipfendra (enlicitide decanoate)

Merck Sharp & Dohme (MRK)

Marketer take

An oral PCSK9 inhibitor that brings the injectable class's mechanism to a pill, which pressures Repatha, Praluent and Leqvio and widens the lipid audience from cardiology into primary care.

Sponsor company
Merck Sharp & Dohme (MRK)
Indication
To reduce low-density lipoprotein cholesterol
Therapeutic area
Cardiovascular
Event
FDA approval
Date
Jul 15, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move